Wnt5a Inhibition in Schlemm's Canal for Glaucoma Pressure Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, such as eye drops and surgeries, have limited efficacy and side effects, and there is no cure for the disease, which is often caused by elevated intraocular pressure due to increased resistance in Schlemm's canal, leading to optic nerve damage and blindness.
Innovation Solution
Locally administering a Wnt5a inhibitor, such as siRNA, antibodies, or small molecule inhibitors, via eye drops, injections, or ophthalmic formulations to target Schlemm's canal and reduce intraocular pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional eye drops or oral medications are used to treat glaucoma, then some reduction in intraocular pressure may be achieved, but the treatment has limited efficacy and produces many side effects
Solution Approach 1:
The patent uses Wnt5a inhibitor as an intermediary substance to block the pathological Wnt5a signaling pathway in Schlemm's canal. This mediator specifically targets the disease mechanism without the broad systemic effects of conventional medications, thereby improving efficacy while reducing side effects through localized, mechanism-specific intervention
Solution Approach 2:
The invention delivers the Wnt5a inhibitor locally to Schlemm's canal through topical eye drop formulation, concentrating the therapeutic effect at the site of pathology. This local delivery approach ensures high efficacy at the target site while minimizing systemic exposure and associated side effects
2Reliability
If surgeries are performed to treat glaucoma, then intraocular pressure can be reduced, but the surgery often fails with scar formation and fibrosis
Solution Approach 1:
The patent replaces the mechanical surgical intervention with a biochemical therapy using Wnt5a inhibitor. Instead of physically altering Schlemm's canal structure through surgery, the inhibitor modulates the molecular signaling pathway, avoiding mechanical trauma and the subsequent scar formation and fibrosis that characterize surgical outcomes
Solution Approach 2:
The Wnt5a inhibitor is administered as a topical eye drop that can be easily applied and replaced. This disposable, non-invasive approach eliminates the permanent structural changes and scarring associated with surgical procedures, allowing for reversible and adjustable treatment
3Reliability
If Schlemm's canal resistance increases with age or under pathological conditions, then intraocular pressure is elevated leading to glaucoma, but there is no cure for the disease
Solution Approach 1:
The patent changes the biochemical parameter of Wnt5a signaling activity in Schlemm's canal by introducing a Wnt5a inhibitor. This parameter change reverses the pathological resistance increase associated with aging and glaucoma, restoring normal aqueous humor outflow and providing a curative treatment option where none previously existed
Data Source
AI summary
Glaucoma or pathogenic intraocular pressure is treated by locally administering to an eye in need thereof formulations of a Wnt5a inhibitor.